32 results about "Ejection fraction" patented technology

An example system for determining reduced ejection fraction includes two or more electrodes forming a single lead configured to capture a cardiac electrogram (EGM) signal of a patient, circuitry configured to: convert the EGM signal to a time -frequency domain using a continuous wavelet transform; and apply the converted EGM signal to a convolutional neural network to determine one or more of an amount of ejection fraction or a classification of ejection fraction.

An apparatus for producing information indicative of a heart failure with reduced ejection fraction HFrEF comprises a signal interface 101 for receiving a signal indicative of cardiac angular rotation

The invention discloses a heart failure biomarker and application thereof, relates to the technical field of biology, solves the technical problem that BNP is insufficient in early signal recognition of HFpEF, and is characterized by providing a biomarker LECT2 protein or LECT2 coding gene for diagnosis or auxiliary diagnosis of heart failure. The invention provides application of a product for quantitatively detecting LECT2 protein in preparation of a tool for diagnosing heart failure, the heart failure is ejection fraction retention type heart failure, a pharmaceutical composition for treating HFpEF is provided, the pharmaceutical composition comprises an LECT2 inhibitor, and the inhibitor is selected from one or more of shRNA of a targeted LECT2 gene, an antibody of the targeted LECT2 protein and an antagonist of a targeted LECT2 receptor; the effects of being beneficial to early recognition of high-risk patients and remarkably improving the accuracy of HFpEF diagnosis and the early detection capability are achieved.

The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.

The invention relates to a viral vector carrying a Prrg3 gene expression cassette and application thereof in treating diseases. Specifically, the invention relates to a Prrg3 gene expression cassette, a virus vector carrying the Prrg3 gene expression cassette and application of the virus vector in treatment of heart failure, cardiac hypertrophy, hypertension, overweight, obesity, diabetes, fatty liver, hyperlipidemia and other diseases, and the virus vector is especially suitable for ejection fraction retention heart failure patients with one or more diseases. The application provides a new thought and strategy for clinical treatment of ejection fraction retention heart failure and complications thereof, and has a wide application prospect.

This invention discloses a heart failure readmission risk assessment system based on cardiac imaging feature analysis, belonging to the field of cardiac imaging analysis technology. By analyzing speckle texture features in ultrasound images and combining them with respiratory phase and image quality information, a dynamic and regular quantitative index is generated, thereby achieving accurate risk assessment. It can identify potentially high-risk patients in advance, even those with normal or mildly abnormal ejection fractions, and effectively addresses the impact of respiratory phase changes and image quality interference on assessment results. By weighted fusion of image quality and physiological state information, the stability and accuracy of the assessment results are improved, making it particularly suitable for primary healthcare institutions. This invention provides a more objective and accurate risk assessment, offering a scientific basis for doctors to develop personalized treatment plans, thereby significantly improving the early identification and treatment outcomes of heart failure patients.

Uses of a complex of an angiotensin II receptor antagonist metabolite and a NEP inhibitor in treating heart failure, specifically related are uses of complex in preparing a medicament for use in heart failure with reduced ejection fraction (HFrEF).

The invention discloses an ultrasonic processing method for ejection fraction evaluation, and relates to the field of ultrasonic three-dimensional imaging. The method comprises the steps that an initial heart ultrasonic image set is acquired; classifying and screening all the cardiac ultrasound images to obtain cardiac feature information; performing three-dimensional modeling on the heart to obtain an ultrasonic three-dimensional image; performing time sequence modeling on the ultrasonic three-dimensional image to obtain a dynamic ultrasonic three-dimensional image; when it is judged that the dynamic ultrasonic three-dimensional image does not meet the forming condition, a feedback adjustment step is triggered and executed, and an updated dynamic ultrasonic three-dimensional image is obtained; when it is judged that the updated dynamic ultrasonic three-dimensional image does not meet the forming condition, the feedback adjustment step is triggered and executed again; when it is judged that the updated image meets the forming condition, the ejection fraction corresponding to the heart is obtained. Therefore, the dynamic ultrasonic three-dimensional image can be circularly updated through a feedback adjustment mechanism, so that the dynamic three-dimensional imaging precision is improved, and meanwhile, the EF measurement precision is also improved.

The invention relates to soluble guanylate cyclase (sGC) activators, preferably (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid (runcaciguat) and / or substituted pyrazolo piperidine carboxylic acids, preferably selected from the list consisting of 1-[1-{4-Chloro-4′-[4-(2-methylpropyl)piperazin-1-yl][1,1′-biphenyl]-2-yl}piperidin-3-yl]-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-{3(R)-1-[4-Chloro-4′-(4-isobutylpiperazin-1yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-{3(R)-1-[4-Chloro-4′-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride, 1-{3(R)-1-[4-Chloro-4′-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride hemihydrate or 1-[1-{4-chloro-4′-[4-(2-methylpropyl)piperazin-1-yl][1,1′-biphenyl]-2-yl}piperidin-3-yl]-5-(trifluoro-methyl)-1H-pyrazole-4-carboxylic acid hydrochloride (Enantiomer 1) for use in the treatment and / or prophylaxis of heart failure with preserved ejection fraction (HFpEF) in women and their use for preparing medicaments for the use in the treatment and / or prophylaxis of heart failure with preserved ejection fraction (HFpEF) in women.

This invention provides the use of a reagent overexpressing Parp7 in the preparation of drugs for treating septic cardiomyopathy, belonging to the field of biomedical technology. This invention involves constructing a recombinant adeno-associated virus vector AAV9-F4 / 80- that specifically overexpresses PARP7 on macrophages. Parp7 The drug was intravenously injected into mice, and a septic cardiomyopathy model was established using lipopolysaccharide induction. Experimental results showed that macrophage-specific overexpression of PARP7 significantly reduced serum levels of myocardial injury markers CK-MB and cTnT, improved cardiac function indicators such as ejection fraction and fractional shortening, alleviated myocardial tissue pathological damage, and inhibited macrophage infiltration and inflammatory factors. Ifn-beta , Tnf- α , Il‑6 and Il‑1β The expression of PARP7. This invention reveals the protective role of PARP7 in septic cardiomyopathy, providing a new target and strategy for the treatment of septic cardiomyopathy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of naringin in preparation of a medicine for preventing and / or treating ejection fraction retention type heart failure (HFpEF). A double-strike HFpEF mouse model induced by HFD (High Fat Diet) combined with L-NAME (N omega-nitro-L-arginine methyl ester) is constructed to prove that the naringin can obviously improve metabolic disorder, cardiovascular dysfunction and inflammatory injury of the HFpEF mouse and relieve myocardial hypertrophy and myocardial fibrosis of the mouse; therefore, the effect of preventing and / or treating the ejection fraction retention type heart failure can be achieved, and the naringin can be used as an active ingredient for preparing the medicine for preventing and / or treating the ejection fraction retention type heart failure.

The invention discloses a text prompt type heart function intelligent evaluation method based on a visual language large model. The method comprises the following steps that 1, an echocardiography mark data set is constructed; 2, dividing four chambers of the heart; step 3, hierarchical feature learning; 4, performing multi-scale feature fusion; and 5, predicting the cardiac function (ejection fraction). According to the method, the heart can be modeled into a multi-scale semantic system, and features from macroscopic chamber dynamics to microstructure motion are captured through a hierarchical feature learning mechanism. Deep integration of imaging data and clinical knowledge is realized by aligning hierarchical visual features with professional medical descriptions in a shared semantic space. The method has excellent performance in the aspect of ejection fraction prediction.

The application discloses application of sarcolipin (Sln) in early noninvasive diagnosis of type I ejection fraction reserved heart failure, and belongs to the technical field of early diagnosis of diseases. The application provides application of a reagent for detecting Sln in preparation of a heart failure early diagnosis kit, and the reagent can be used as a sensitive index for early noninvasive diagnosis of HFpEF. It is found in the application that Sln has the strongest correlation with LVEDP and is negatively correlated with LVEDP, which indicates that the content change of Sln can reflect early diastolic dysfunction of myocardium, and significant down-regulation of Sln indicates early occurrence of HFpEF. Meanwhile, the Sln value can reflect early diastolic dysfunction of myocardium, and the Sln value is more sensitive than BNP.

A method for improving an ejection fraction of a patient in need thereof, including positioning a pulmonary artery manipulation device in a target blood vessel, within the pulmonary vasculature of the patient; and impairing the activity of at least one sympathetic nerve, nerve fiber or neuron, using the pulmonary artery manipulation device, to denervate the target blood vessel, thereby improving the ejection fraction of the patient.

Provided is use of an HPCAL1 protein in enhancing cardiac function. The HPCAL1 protein can specifically bind to a recombinant β3-adrenergic receptor, and can be used as a β3-adrenergic receptor antagonist protein. It is found in animal experiments that by intravenously injecting recombinant mouse HPCAL1 with a certain concentration into an ischemia-reperfusion mouse model, the cardiac function of the mice can be effectively improved, and the ejection fraction of the mice is enhanced, indicating that the HPCAL1 protein can be used for enhancing the cardiac function and has potential medicinal value for treating cardiovascular diseases with cardiac function decline. Moreover, the HPCAL1 protein is a class of biomacromolecules with low toxicity, which solves the problem of high hepatic and renal toxicity of small molecule chemical drugs. Therefore, the HPCAL1 protein has relatively high application value.

This invention discloses a method for constructing a predictive model for heart failure and all-cause mortality risk in patients with chronic kidney disease (CKD). It relates to the field of model construction technology, and its key technical points are as follows: This invention uses G3a-G5 stage CKD patients with preserved ejection fraction as the research subjects, establishes a prospective cohort, collects clinical indicators, biomarkers, and quality of life scores, and uses new-onset heart failure combined with all-cause mortality as the composite endpoint. After standardized follow-up and data preprocessing, univariate Cox regression, Lasso, random forest, XGBoost combined with Venn diagrams are used to screen predictive factors. Age, lipoprotein(a), ferritin, GDF15, and EQ-5D quality of life score are identified as independent predictors. A time-dependent nomogram model is constructed, and multi-dimensional efficacy validation is performed. This model is adapted to the specific pathophysiological state of CKD, with accurate predictions and good calibration. With accompanying online interactive tools, it can achieve individualized risk assessment and stratified intervention for 24-36 months, solving the problems of poor applicability and inaccurate prediction in existing models, and has strong clinical applicability.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for improving diabetes mellitus complicated with ejection fraction retention type heart failure, a pharmaceutical preparation, a preparation method and application. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of ginseng, 10-30 parts of astragalus membranaceus, 5-15 parts of coptis chinensis, 5-15 parts of polygonum cuspidatum, 10-30 parts of radix puerariae and 20-40 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating mice, FBG and body weight of the mice are not obviously changed, but the insulin sensitivity can be increased, the high glucose state of cardiac metabolism can be improved, the diastolic dysfunction of DM-HFpEF mice can be relieved, meanwhile, the traditional Chinese medicine composition can relieve cardiac microvascular fibrosis by influencing the EndMT process, and the curative effect is good. The invention further illustrates that the traditional Chinese medicine composition mediates cell autophagy to intervene in'cell failure-EndMT 'to improve the potential action mechanism of cardiac fibrosis.

Techniques for detecting low ejection fraction (EF) from electrocardiogram (ECG) data using artificial intelligence (AI) are disclosed. ECG data is obtained for a patient. The ECG data is provided as input to a plurality of trained AI models, wherein each trained AI model is trained to determine a score of low EF based on the ECG data. A score of low EF is determined using each trained AI model based on the ECG data. An overall score of low EF is determined based on a combination of the scores of low EF determined by each of the trained AI models. An operating point threshold is obtained for the patient based on a plurality of patient characteristics. The overall score of low EF is compared to the operating point threshold. A low EF prediction is made for the patient based on the comparison.

The invention relates to the technical field of cardiac pressure model construction, and discloses an animal cardiac pressure load model construction device, which comprises a data acquisition planning module, a data processing module, a data processing module, a data processing module, a data processing module, a data processing module and a data processing module, wherein the data acquisition planning module acquires basic physiological data such as animal heart rate and blood pressure and plans cardiac pressure load parameters such as target pressure value; the control module deploys a biocompatible air bag with an annular bag body structure on the outer side below the aortic arch of the animal through a neck incision, drives the biocompatible air bag to be periodically inflated and deflated and responds to an adjustment instruction; the monitoring and adjusting module collects data such as cardiac pressure and ejection fraction in real time, and generates an adjusting instruction after comparing the data with planning parameters; and the management module terminates inflation and deflation after the experiment reaches the standard, dissects, acquires and numbers heart tissue samples, binds associated experiment data, and stores the data to form a data set. According to the invention, the accuracy and reliability of heart-related experiments are obviously improved, and comprehensive and associated experiment support is provided for subsequent research.

Provided are methods for constructing animal models of heart failure combined with pulmonary arterial hypertension, including an animal model of heart failure combined with pulmonary arterial hypertension with preserved ejection fraction and an animal model of heart failure combined with pulmonary arterial hypertension with reduced ejection fraction.

To provide generation of information indicative of heart failure with reduced ejection fraction "HFrEF".SOLUTION: An apparatus for generating information indicative of heart failure with reduced ejection fraction (HFrEF) includes a signal interface (101) for receiving a signal indicative of cardiac angular rotation and a processing system (102) coupled to the signal interface. The processing system is configured to extract from the signal a temporal portion belonging to a diastolic phase of the heart. The processing system is configured to configure an output signal of the apparatus to represent the presence of heart failure with reduced ejection fraction based on a result of the comparison between the indicator quantity and the threshold value.SELECTED DRAWING: Figure 1

A drive transfer system (40) configured to drive a remote implantable medical device (1) configured to treat disease, the system (40) comprising a motor (42) configured to actuate an implantable medical device (1), a controller device (41) communicable with the motor (42) configured to modify the output parameters of the motor (42) in accordance with the treatment required, and a drive shaft (8) configured to operably connect the motor (42) to the implantable medical device (1) to drive the implantable medical device (1) when the motor (42) is located remotely from the implantable medical device (1). The system of the invention finds particular utility in the treatment of cardiac diseases such as heart failure with preserved ejection fraction (HFpEF).

Provided are an ultrasound diagnostic apparatus capable of easily calculating an ejection fraction of a cavity of a heart in a short time and a method of controlling the ultrasound diagnostic apparatus.An ultrasound diagnostic apparatus includes: an image acquisition unit that acquires first ultrasound images in which a first cross section of a heart is imaged, and second ultrasound images in which a second cross section of the heart is imaged; a cross-sectional area calculation unit that calculates a cross-sectional area of a cavity of the heart for the first ultrasound images and the second ultrasound images; a cross-sectional area change curve generation unit that generates a first cross-sectional area change curve of the first cross section and a second cross-sectional area change curve of the second cross section; an alignment unit that aligns the first cross-sectional area change curve and the second cross-sectional area change curve with each other; and a frame update unit that, in a case in which one frame of the first ultrasound image or the second ultrasound image is updated based on an instruction from a user, automatically updates the other frame.

The invention discloses an application of repiperidine in heart protection. The invention relates to an application of repiperidine in preparation of a medicine for treating and / or preventing myocardial infarction. Before myocardial infarction operation, a mouse is pretreated by repiperidine, so that the number of reactive oxygen species (ROS) positive cells and TUNEL positive cells is reduced. After the repiperidine is used for pretreatment, the myocardial infarction area of the mouse is reduced, and the ejection fraction (EF%) of the mouse with myocardial infarction is improved.

The present application relates to the field of biological detection, and particularly relates to application of IGSF1 protein as a marker for heart function recovery. The present application provides application of a protein as a marker in preparation of a product for detecting and / or diagnosing heart failure with improved ejection fraction; the protein comprises one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4. The present application provides a novel serum marker, expression level of which can accurately predict a heart failure patient with reduced ejection fraction and potential for heart function recovery, and change earlier than that of ejection fraction. The present application establishes a non-invasive standardized detection process based on serum samples, which is suitable for medical institutions at all levels, and realizes early and non-invasive prediction of heart function recovery potential of heart failure patients.

The present invention provides an ultrasound diagnostic device and a control method for the ultrasound diagnostic device that can quickly and easily calculate the ejection fraction of the cardiac lumen. [Solution] The ultrasound diagnostic device includes an image acquisition unit (33) that acquires a first ultrasound image of a first cross-section of the heart and a second ultrasound image of a second cross-section of the heart; a cross-sectional area calculation unit (24) that calculates the cross-sectional area of ​​the lumen of the heart based on the first ultrasound image and the second ultrasound image; a cross-sectional area change curve generation unit (25) that generates a first cross-sectional area change curve for the first cross-section and a second cross-sectional area change curve for the second cross-section; a positioning unit (26) that aligns the first cross-sectional area change curve and the second cross-sectional area change curve with respect to each other; and a frame update unit (29) that automatically updates the other frame when one of the frames of the first ultrasound image and the second ultrasound image is updated based on user instructions.

A system for tracking cardiac values including at least a processor configured to receive electrocardiogram (ECG) input data associated with a patient wherein the ECG input data includes ECG signals, input the ECG input data into one or more cardiac panels, wherein each cardiac panel of the one or more cardiac panels is configured to calculate a cardiac value associated with a heart condition and each cardiac panel comprises at least one ECG machine-learning model configured to receive ECG input data and output cardiac values, generate the cardiac values from the cardiac panels as a function of the ECG input data wherein at least one cardiac value of the one or more cardiac values includes a probability of the patient satisfying at least one ejection fraction level threshold and the one or more ECG machine-learning models and display the cardiac values through a graphical user interface.

The application provides a reduced ejection fraction and intermediate heart failure drug treatment prognosis risk score and application thereof, in particular, a multi-gene genetic risk score for affecting the prognosis of a reduced ejection fraction and intermediate heart failure by a beta-receptor blocker and application thereof. The application establishes a reduced ejection fraction and intermediate heart failure drug treatment prognosis risk PRS score based on multi-gene single nucleotide polymorphism sites, and the reduced ejection fraction and intermediate heart failure population sensitive to the beta-receptor blocker can be well identified.

Techniques for detecting low ejection fraction (EF) from electrocardiogram (ECG) data using artificial intelligence (AI) are disclosed. ECG data is obtained for a patient. The ECG data is provided as input to a plurality of trained AI models, wherein each trained AI model is trained to determine a score of low EF based on the ECG data. A score of low EF is determined using each trained AI model based on the ECG data. An overall score of low EF is determined based on a combination of the scores of low EF determined by each of the trained AI models. An operating point threshold is obtained for the patient based on a plurality of patient characteristics. The overall score of low EF is compared to the operating point threshold. A low EF prediction is made for the patient based on the comparison.

The present invention relates to certain benzodihydropyranol, quinone or hydroquinone compounds and their derivatives for use in the treatment of heart failure with reduced ejection fraction (HFrEF). In particular, the present invention relates to chromanol compounds selected from the group consisting of S-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl) (piperazin-1-yl) methanone and S-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl) (4-(2-hydroxyethyl) piperazin-1-yl) methanone, and pharmaceutically acceptable salts thereof.